The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
Gavin P Reynolds
Psychiatry Investig. 2012;9(1):1-7.   Published online 2012 Jan 9     DOI: https://doi.org/10.4306/pi.2012.9.1.1
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates
Antonio Vita, Alessandra Minelli, Stefano Barlati, Giacomo Deste, Edoardo Giacopuzzi, Paolo Valsecchi, Cesare Turrina, Massimo Gennarelli
Frontiers in Pharmacology.2019;[Epub]     CrossRef
Biological Predictors of Clozapine Response: A Systematic Review
Ruta Samanaite, Amy Gillespie, Kyra-Verena Sendt, Grant McQueen, James H. MacCabe, Alice Egerton
Frontiers in Psychiatry.2018;[Epub]     CrossRef
Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients
Hong-Qiang Sun, Su-Xia Li, Fang-Bin Chen, Yan Zhang, Peng Li, Mei Jin, Yan Sun, Fan Wang, Wei-Feng Mi, Le Shi, Jing-li Yue, Fu-De Yang, Lin Lu
Psychoneuroendocrinology.2016; 64: 108.     CrossRef
Pharmacogenetic studies of drug response in schizophrenia
MJ Arranz, C Gallego, J Salazar, B Arias
Expert Review of Precision Medicine and Drug Development.2016; 1(1): 79.     CrossRef
Minor physical anomalies and craniofacial measures in patients with treatment-resistant schizophrenia
A.-S. Lin, S.-S. Chang, S.-H. Lin, Y.-C. Peng, H.-G. Hwu, W. J. Chen
Psychological Medicine.2015; 45(9): 1839.     CrossRef
Hypothalamic–pituitary–adrenal system, neurotrophic factors and clozapine response
Marina Mitjans, Rosa Catalán, Mireia Vázquez, Alex González-Rodríguez, Rafael Penadés, Alexandre Pons, Guillem Massana, Janet Munro, Maria J. Arranz, Bárbara Arias
Pharmacogenetics and Genomics.2015; 25(5): 274.     CrossRef
Positive perception of pharmacogenetic testing for psychotropic medications
Matthew B. Lanktree, Gwyneth Zai, Laura E. VanderBeek, Daniel E. Giuffra, David S. Smithson, Lucas B. Kipp, Timothy R. Dalseg, Mark Speechley, James L. Kennedy
Human Psychopharmacology: Clinical and Experimental.2014; 29(3): 287.     CrossRef
Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study
C. Nordon, F. Rouillon, J. M. Azorin, C. Barry, M. Urbach, B. Falissard
Acta Psychiatrica Scandinavica.2014; 129(2): 116.     CrossRef
Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia
Brett A English, Kelan Thomas, Jack Johnstone, Adam Bazih, Lev Gertsik, Larry Ereshefsky
Biomarkers in Medicine.2014; 8(1): 29.     CrossRef
Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight
Amtul H. Changasi, Tahireh A. Shams, Jennie G. Pouget, Daniel J. Müller
Translational Developmental Psychiatry.2014; 2(1): 24663.     CrossRef
Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial
Anne Katrine Pagsberg, Pia Jeppesen, Dea Gowers Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Peter Jantzen, Simone Rasmussen, Eva Ann-Sofie Saldeen, Maj-Britt Glenn Lauritsen, Niels Bilenberg, Anne Dorte Stenstrøm, Jesper Peders
BMC Psychiatry.2014;[Epub]     CrossRef
What effect will pharmacogenomics have on mental health nursing?
Thomas J Currid, Stanley Mutsatsa
Neuropsychiatry.2013; 3(3): 309.     CrossRef
Pharmacogenetics in schizophrenia: a review of clozapine studies
Fabiana Barzotti Kohlrausch
Revista Brasileira de Psiquiatria.2013; 35(3): 305.     CrossRef
Calorimetric monitoring of the serum proteome in schizophrenia patients
Sashka Krumova, Blaga Rukova, Svetla Todinova, Lidia Gartcheva, Vihra Milanova, Draga Toncheva, Stefka G. Taneva
Thermochimica Acta.2013; 572: 59.     CrossRef
Next-generation sequencing of pharmacogenes
Britt I. Drögemöller, Galen E.B. Wright, Dana J.H. Niehaus, Robin Emsley, Louise Warnich
Pharmacogenetics and Genomics.2013; 23(12): 666.     CrossRef
Personalized medicine in psychiatry: problems and promises
Uzoezi Ozomaro, Claes Wahlestedt, Charles B Nemeroff
BMC Medicine.2013;[Epub]     CrossRef